Astellas, Seagen: Cancer Treatment Padcev Supplemental Biologics License Application Gets FDA Priority Review
By Stephen Nakrosis
Astellas Pharma and Seagen said the Food and Drug Administration has accepted for priority review a supplemental biologics license application for Padcev in combination with Keytruda to treat certain adult patients with bladder cancer.
The combination therapy of Padcev, or enfortumab vedotin-ejfv, and Keytruda is being studied as a treatment for adult patients with locally advanced or metastatic urothelial cancer, the companies said. Keytruda, an immunotherapy marketed by Merck, works with the body's immune system to help fight cancer, the company said Thursday.
Results from a pivotal confirmatory trial found the combination "significantly extended overall survival and progression-free survival versus standard platinum containing chemotherapy," according to Astellas.
It is estimated that 82,290 people will be diagnosed with bladder cancer in the U.S. this year, according to the companies.
Write to Stephen Nakrosis at stephen.nakrosis@wsj.com
(END) Dow Jones Newswires
November 30, 2023 17:49 ET (22:49 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
5 Undervalued Stocks to Buy to Play a Little Defense
-
Markets Brief: AI Leaders Excel In Earnings Season So Far
-
What History Tells Us About the Fed’s Next Move
-
What’s Happening In the Markets This Week
-
Alphabet’s New Dividend: What Investors Need to Know
-
Going Into Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
Going Into Earnings, Is Eli Lilly Stock a Buy, a Sell, or Fairly Valued?
-
What’s the Difference Between the CPI and PCE Indexes?
-
After Earnings, Is Tesla Stock a Buy, a Sell, or Fairly Valued?
-
After Earnings, Is GE Aerospace Stock a Buy, a Sell, or Fairly Valued?
-
3 Good Stocks to Buy with Your Tax Refund in 2024 (Or with Any Extra Money)
-
SoFi Earnings: Revenue Growth Slows on Lower Loan Growth and Higher Credit Costs
-
Tesla: Full Self-Driving Approval In China Supports Our View for Deliveries Growth In 2024
-
Philips Earnings: Firm Reaches $1.1 Billion Settlement Agreement
-
AbbVie Earnings: Next-Generation Immunology Drugs Help Offset Humira Biosimilar Pressure
-
Exxon Earnings: Ignore Earnings Shortfall as Long-Term Growth and Improvement on Track